Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zyclara (Imiquimod),ZCL2020USA,2020,USA,MDV,350,62,45,55,27.5,32,92,5,55,30,10,5,70,20,7,3,60,25,15,12,4,2,6,3,8,15,20,None,None,None,None,0,0,0,10,5,25,20,50,30,15,2
Zyclara (Imiquimod),ZCL2021CAN,2021,Canada,Claim database,420,68,52,48,28.1,35,90,7,60,25,10,5,75,15,6,4,65,20,15,15,5,3,7,4,7,12,18,None,None,None,None,0,0,0,12,6,28,25,45,30,18,1.5
Zyclara (Imiquimod),ZCL2022EUR,2022,Germany,MDV,280,70,48,52,26.9,30,88,6,58,27,9,6,72,18,5,5,62,23,15,14,6,2,8,5,9,14,22,None,None,None,None,0,0,0,11,7,27,18,52,30,20,2.5
